Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Combination therapy

    FDA Approves Nivolumab in Combination With Chemotherapy and in Combination With Ipilimumab for First-Line Esophageal Squamous Cell Carcinoma Indications
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab in Combination With Chemotherapy and in Combination With Ipilimumab for First-Line Esophageal Squamous Cell Carcinoma Indications

    On May 27, 2022, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based chemotherapy and nivolumab in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).

    June 02, 2022
    Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy
    Cancer research

    Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy

    Combination treatment with an oncolytic virus plus a PD-1 inhibitor shows promise in patients with nonmelanoma skin cancers, researchers reported in early study results during the 2022 Multidisciplinary Head and Neck Cancers Symposium.

    May 25, 2022
    First-Line Combination Immunotherapy Prolongs Survival in BRAF Advanced Melanoma
    Cancer research

    First-Line Combination Immunotherapy Prolongs Survival in BRAF Advanced Melanoma

    Initial treatment with two monoclonal antibodies significantly improves survival for patients with BRAF V600-variant advanced melanoma compared to treatment with two targeted agents, researchers reported during the November 2021 ASCO Plenary Series meeting. The initial findings were so conclusive that the study’s data safety and monitoring board stopped the trial early.

    April 20, 2022
    Evidence Defines Nursing Implications for Combination Cancer Treatment Side Effects
    Combination therapy

    Evidence Defines Nursing Implications for Combination Cancer Treatment Side Effects

    Immune checkpoint inhibitors (ICIs) enhance immune response against foreign antigens, such as cancer, by manipulating checkpoints that have stopped the body from fighting them. In doing so, they also increase risk of the immune system attacking healthy cells and producing inflammatory side effects, resulting in immune-related adverse events (irAEs).

    February 08, 2022
    Nursing Considerations for Isatuximab Combination Therapy
    Combination therapy

    Nursing Considerations for Isatuximab Combination Therapy

    Clinicians often use combination cancer therapies to overcome treatment resistance, and one of the newest options for certain patients with multiple myeloma is isatuximab, a monoclonal antibody (mAb). Approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received at least two prior therapies, isatuximab prolonged progression-free survival by nearly six months and produced an overall response rate of more than 60% in the drug’s clinical trials.

    February 08, 2022
    Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer
    Cancer research

    Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer

    Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.

    February 02, 2022
    The Pharmacist’s Role in Combination Cancer Treatments
    Combination therapy

    The Pharmacist’s Role in Combination Cancer Treatments

    Since the first checkpoint inhibitor was approved in 2011, we have made tremendous leaps in immunotherapy in a short span of 10 years. Now we see immunotherapy combined with a variety of options, including chemotherapy or other oral and IV targeted therapy.

    February 01, 2022
    Today’s Immunotherapy Combinations
    Immunotherapy

    Today’s Immunotherapy Combinations

    Immunotherapy has revolutionized cancer treatment, especially for patients with diseases considered otherwise incurable. Since May 2017, the U.S. Food and Drug Administration (FDA) has approved 27 immunotherapy combinations, including chemoimmunotherapy and regimens with targeted therapies, and researchers are reporting highly promising data from clinical trials of its combination with radiation.

    February 01, 2022
    The Case of Concurrent Therapy Concerns
    Treatment side effects

    The Case of Concurrent Therapy Concerns

    Sharon is a 60-year-old woman with metastatic breast cancer that was originally diagnosed in 2005 and treated with a mastectomy, deep inferior epigastric artery perforator flap reconstruction, chemotherapy, post mastectomy radiation, and five years of tamoxifen. Three months ago, her breast cancer recurred, and staging scans demonstrated metastatic disease in the lungs, left axilla, liver, and left iliac bone. A biopsy of the left iliac bone was ER positive, PR negative, and HER2 negative. Sharon began treatment with radiation to the painful left hip and letrozole, with the plan to start palbociclib once radiation was completed. 

    December 18, 2020
    The Case of the Thyroid Tradeoff
    Clinical practice

    The Case of the Thyroid Tradeoff

    Tesla is a 24-year-old woman diagnosed with stage IIIA Hodgkin lymphoma. She enrolled in a clinical trial where she received a combination of chemotherapy and immunotherapy with pembrolizumab, an anti-PD-1 antibody. The clinical trial protocol required three doses every three weeks. At baseline, her thyroid function tests were normal. When she presented for her third dose, her labs showed grade 2 hyperthyroidism.

    July 17, 2020
    Which of the Following Drug Is Most Likely to Have a Synergistic Effect When Combined With Radiation Therapy?
    Treatments

    Which of the Following Drug Is Most Likely to Have a Synergistic Effect When Combined With Radiation Therapy?

    Which of the Following Drug Is Most Likely to Have a Synergistic Effect When Combined With Radiation Therapy?

    A. Amifostine 

    B. Pentoxifylline 

    C. Palifermin 

    D. Ipilimumab

    February 01, 2019
    FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Squamous NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Squamous NSCLC

    On October 30, 2018, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

    October 31, 2018
    FDA Grants Approval for Pembrolizumab in Combination with Chemotherapy for First-line Treatment of Metastatic Nonsquamous NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Approval for Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC

    On August 20, 2018, the U.S. Food and Drug Administration (FDA) approved pembrolizumab in combination with pemetrexed and platinum as first-line treatment of patients with metastatic, non-squamous non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations.

    August 20, 2018
    FDA Approves Encorafenib and Binimetinib in Combination
    U.S. Food and Drug Administration (FDA)

    FDA Approves Encorafenib and Binimetinib in Combination for Unresectable or Metastatic Melanoma With BRAF Mutations

    On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved encorafenib and binimetinib (Braftovi and Mektovi) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

    June 28, 2018
    Immunotherapy Plus Chemo Improves Survival in Metastatic Lung Cancer
    Immunotherapy

    Immunotherapy Plus Chemo Improves Survival in Metastatic Lung Cancer

    Combining pembrolizumab and platinum chemotherapy plus pemetrexed doubles survival in patients with nonsquamous non-small cell lung cancer (NSNSCLC) without EGFR or ALK gene mutations, according to the results of a study published in the New England Journal of Medicine.

    June 06, 2018
    ONS Congress

    Combination Drug Offers New Treatment Option for Relapsed Metastatic Colorectal Cancer

    More than 130,000 new cases of colorectal cancers (CRCs) are diagnosed in the United States each year, representing 8% of all new annual cancer cases. The rate of patients with CRC surviving more than five years is 65.1%; however, patients with metastatic disease (mCRC) have a poorer prognosis, with only 13.5% surviving more than years. As many as 40% of patients with mCRC remain candidates for third-line therapy, with some patients requiring up to five lines of therapy because of drug resistance.

    July 01, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Dabrafenib and Trametinib Combination for Metastatic NSCLC with BRAF V600E Mutation

    On June 22, 2017, the U.S. Food and Drug Administration granted (FDA) regular approvals to dabrafenib and trametinib (Taflinar® and Mekinist®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.

    June 23, 2017
    Combination therapies
    Melanoma

    Combination Treatment Improves Survival for Advanced Melanoma

    A combination of nivolumab and ipilimumab improved overall survival when compared to either drug alone, according to results from a recent study reported at the American Association for Cancer Research 2017 annual meeting.

    June 21, 2017
    ASCO Annual Meeting

    Chemotherapy Plus Radiotherapy Not Superior to Radiotherapy Alone in Improving Survival for Patients With High-Risk Endometrial Cancer

    Women with high-risk endometrial cancer (EC) are at an increased risk of metastasis and death. The randomized, intergroup PORTEC-3 study assessed the benefit of adjuvant chemotherapy during and after radiotherapy (RT) versus pelvic RT alone in this patient population. The researchers presented the study at the ASCO Annual Meeting.

    June 02, 2017
    Caring for Multiple Patients
    Clinical practice

    The Challenge of Caring for Multiple Patients With Cancer

    As more new treatments enter practice—like immunotherapy, targeted therapy, and combination therapies—oncology nurses are required to be experts in every treatment they administer. They need to constantly walk a tightrope, balancing multiple medications for one patient then quickly moving to the next patient on a completely different treatment protocol.

    May 17, 2017
    Bortezomib May Improve Outcomes in Multiple Myeloma
    Multiple myeloma

    Bortezomib May Improve Outcomes in Multiple Myeloma

    Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet.

    April 12, 2017
    Cancer treatments

    Combination Therapy Shows Promise for Chronic Myeloid Leukemia

    According to the results of a new study published in Science Translational Medicine, a combination regimen consisting of a BCR-ABL tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor may one day result in a cure for chronic myeloid leukemia.
    January 03, 2017
    Cancer treatments

    Radiation Plus Chemotherapy Improves Survival From Low-Grade Gliomas

    A new study has shown that patients with grade 2 gliomas who are treated with radiation therapy plus a combination of chemotherapy have better survival than patients treated with radiation alone. The findings were published in the New England Journal of Medicine.
    June 01, 2016
    Combination therapy

    FDA Approves Carfilzomib in Combination With Lenalidomide and Dexamethasone for Treatment of Relapsed Multiple Myeloma

    On July 24, 2015, the U.S. Food and Drug Administration approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
    July 24, 2015
    Combination therapy

    FDA Approves Combination of Mekinist and Tafinlar for Advanced Melanoma

    The U.S. Food and Drug Administration (FDA) granted accelerated approval to trametinib (Mekinist tablets, GlaxoSmithKline, LLC) and dabrafenib (Tafinlar capsules, GlaxoSmithKline, LLC) for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test.
    January 10, 2014
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲